ProKidney Corp.
ProKidney Corp.
Your view on PROK
Overview
What the company does, where it operates, and who runs it.
About ProKidney Corp.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Bruce Culleton
- Headquarters
- 2000 Frontis Plaza Blvd., Winston-Salem, NC, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Bruce Culleton
- Headquarters
- 2000 Frontis Plaza Blvd., Winston-Salem, NC, US
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates.
It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract.
The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for ProKidney Corp., and the rating behind it. PROK last traded at $1.36; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for ProKidney Corp.. Starting points for ProKidney Corp.: EPS -$0.46, beta 1.80 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for ProKidney Corp.. ProKidney Corp. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for ProKidney Corp.. Trailing twelve-month EPS for ProKidney Corp. stands at -$0.46. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for ProKidney Corp.. ProKidney Corp. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
ProKidney Corp. valued side by side against its closest peers. ProKidney Corp. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold ProKidney Corp., and how their positions are changing. At a $457.3M market value, institutional positions materially move ProKidney Corp.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by ProKidney Corp. executives and directors. Shares of ProKidney Corp. have traded between $0.46 and $7.13 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming ProKidney Corp.. ProKidney Corp. is a $457.3M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming ProKidney Corp.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for ProKidney Corp.. Coverage tracks ProKidney Corp. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.